Slide 1: Corporate Deck June 2025
Exhibit 99.1 Corporate Deck June 2025
Slide 2: Important Information
Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words su
Slide 3: Full-stack Recursion OS is industrializing first-in-class & best-in-class drug discovery
Full-stack Recursion OS is industrializing first-in-class & best-in- class drug discovery 3
Slide 4: Multi-pronged capital efficient business strategy: pipeline, partnership, data
We harness value from the Recursion OS with a multi-pronged capital efficient business strategy Pipeline strategy • Oncology • Rare disease Build internal pipeline in indications with • Other areas of high potential for advance transformational unmet need medicines for patients Partnership strategy
Slide 5: Pipeline: Advancing 5+ high-potential programs across oncology and rare disease
Pipeline: Advancing 5+ high-potential programs across oncology and rare disease Candidate Target BIC/FIC Indication Preclinical IND-Enabling Phase 1 / 2 Phase 3 1 ELUCIDATE REC-617 CDK7 BIC Advanced solid tumors Biomarker-enriched solid FIC DAHLIA REC-1245 RBM39 tumors & lymphoma EXCELERIZE REC-3565
Slide 6: Pharma partnerships with approximately $455M earned to date
1 Pharma partnerships with approximately $455M earned to date and potential to receive more than $20B in additional milestones NEUROSCIENCE & ONCOLOGY • $150M upfront | Up to $300M per program for 40 programs • Identifying novel targets and small molecules, with the potential to advance up to 40 pro
Slide 7: Recursion OS moves medicines to clinic faster and at a lower cost
Recursion OS moves medicines to clinic faster and at a lower cost Quickly validate Highly productive hypotheses compound design Spend less Go faster 60 14 3,000 30 12 50 2,500 25 10 2,000 20 40 8 1,500 15 30 6 1,000 10 20 4 5 500 10 2 0 0 0 0 Industry Recursion Industry Recursion Industry Recursion
Slide 8: Full-stack Recursion OS is industrializing drug discovery
Full-stack Recursion OS is industrializing first-in-class & best-in- class drug discovery 8
Slide 9: The race to accurately simulate biology at scale
The race to accurately simulate biology at scale MACRO Real-world patient data + AI Patient Models Largest, fit-for-purpose perturbative biology + foundation Pathway Model models make Recursion a leader Increasingly commoditized – Introducing Boltz-2 with MIT Protein Model and NVIDIA Compute Recipe
Slide 10: Boltz-2: Towards accurate and efficient binding affinity prediction
Boltz-2: Towards accurate and efficient binding affinity prediction • Boltz-2: Next-generation biomolecular foundation model allowing for integration of protein model to achieve complete biological systems view • Powered by Recursion's NVIDIA supercomputer for training and validation • Extends inter
Slide 11: Pipeline
Pipeline
Slide 12: Pipeline: Advancing 5+ high-potential programs across oncology and rare disease
Pipeline: Advancing 5+ high-potential programs across oncology and rare disease Candidate Target BIC/FIC Indication Preclinical IND-Enabling Phase 1 / 2 Phase 3 1 ELUCIDATE REC-617 CDK7 BIC Advanced solid tumors Biomarker-enriched solid FIC DAHLIA REC-1245 RBM39 tumors & lymphoma EXCELERIZE REC-3565
Slide 13: Targeted, differentiated portfolio strategy
Targeted, differentiated portfolio strategy Powered by the Recursion OS 2.0 platform Double down on areas of expertise and efficiency Oncology・I&I・Neuroscience・Rare Explore the uncharted by going after novel targets to develop differentiated medicines First-in-class molecules Differentiated, product
Slide 14: Sharpening our focus: Pipeline programs powered by Recursion OS
Sharpening our focus: Pipeline programs powered by Recursion OS REC-617 | CDK7 REC-1245 | RBM39 REC-4881 | MEK1/2 Ph 1/2 Mono; Ph 1 Combo 1H25 Ph 1 Ph 1b/2 1 2 Familial adenomatous polyposis (FAP) Solid tumors Solid tumors , Lymphoma Phenotypic insight to identify novel MOA Phenotypic insight on MEK
Slide 15: REC-617 (CDK7 inhibitor): Summary & next steps
REC-617 (CDK7 inhibitor): Summary & next steps Monotherapy dose escalation ongoing with update 2H25; Combination study to initiate 1H25 Recursion OS Insight Preclinical Validation Clinical Development 1 CDX Model: OVCAR CDKC IC (nM) 50 Target affinity and selectivity CDK family selectivity HCC70 (br
Slide 16: REC-1245 (RBM39 degrader): Summary & next steps
REC-1245 (RBM39 degrader): Summary & next steps Monotherapy dose escalation ongoing with preliminary update 1H26 Recursion OS Insight Preclinical Validation Clinical Development REC-1245 1 CDX Model: OVK18 Illustrative example Opposite Similar Identified through phenotypic Compelling efficacy and PK
Slide 17: REC-3565 (MALT1 inhibitor): Summary & next steps
REC-3565 (MALT1 inhibitor): Summary & next steps Monotherapy dose escalation ongoing with preliminary update 2H26 Recursion OS Insight Preclinical Validation Clinical Development 1 CDX Model: OCI-Ly10 Illustrative example 344 novel compounds to Candidate ID Designed to deliver balanced Single-agent
Slide 18: REC-4881 (MEK1/2 inhibitor): Summary & next steps
REC-4881 (MEK1/2 inhibitor): Summary & next steps Phase 2 dose expansion ongoing with update 2H25 Recursion OS Insight Preclinical Validation Clinical Development min/+ 1 In Vivo Model: APC REC-4881 suppresses disease-inducing effects of APC mutations Identified through phenotypic Significant reduct
Slide 19: REC-7735: PI3Kα H1047R – Summary & next steps
REC-7735: PI3K⍺ H1047R – Summary & next steps Biological Insight High selectivity for H1047R mutant PI3K⍺ over WT to reduce dose-limiting hyperglycemia REC-7735 Target Profile • Potential best-in-class PI3K⍺ H1047R inhibitor Design • >100-fold selective against WT PI3K⍺ AI-driven generative design v
Slide 20: REV102: ENPP1 – Next steps
REV102: ENPP1 – Next steps Biological Insight Reduction of PPi production via controlled ENPP1 inhibition REV102 Target Profile to restore bone hypomineralization • Potential first-in-class ENPP1 inhibitor • High oral bioavailability supports QD or Design BID dosing AI-driven generative design via f
Slide 21: Partnered Programs
Partnered Programs
Slide 22: Sanofi collaboration advancing novel targets in I&I and oncology
Sanofi collaboration advancing novel targets in I&I and oncology – 4 milestones achieved, multiple additional expected Program milestones Biology Design Optimize achieved 4 to date 1 Leveraging suite of tools tailored for each program to collaboratively identify and drive up to Development Candidate
Slide 23: Roche and Genentech collaboration within neuroscience and GI oncology
Roche and Genentech collaboration within neuroscience and GI oncology indication – unbiased novel biological insights to programs Design Biology Optimize ~5 Phenomaps Lab in the Loop Derived from over 1 trillion iPSC cells and What’s next 100 billion GI Onc relevant cells • Additional phenomap build
Slide 24: Financial Update
Financial Update
Slide 25: Streamlining operations to advance platform, pipeline & partnerships
Streamlining operations to advance platform, pipeline & partnerships Cash, cash equivalents and 2 3 Expected cash burn Partnership inflows restricted cash 2 • Expected 2025 cash burn of • $7 million Sanofi milestone 1 • $509.2 million in cash as of <$450 million payment achieved in 2Q25 March 31, 20
Slide 26: Looking Forward
Looking Forward
Slide 27: Solidifying Recursion's leadership in TechBio
Solidifying Recursion’s leadership in TechBio Our sustainable and continued growth plan • Commitment to internal pipeline – Strong investment behind more focused pipeline • Execution on partnerships – Fully resourced to deliver on programs and achieve milestones • Transforming drug discovery and dev
Slide 28: Internal and external pipeline momentum: upcoming catalysts
Internal and external pipeline momentum FY 2025 and 2026 upcoming pipeline catalysts H1 H2 H1 H2 REC-4881 (MEK1/2i) in FAP REC-617 (CDK7i) in REC-1245 (RBM39 degrader) REC-3565 (MALT1i) Additional safety and efficacy advanced solid tumors Early safety and PK from Early safety and PK from data from T
Slide 29: Recursion
gS Recursion.